Skip to main content
. 2021 May 19;59(6):e03161-20. doi: 10.1128/JCM.03161-20

TABLE 3.

Results and calculated sensitivities, with equivocal results counted as either negative or positive, of the commercial methods for the detection of anti-measles IgM antibodies evaluated with the measles sera panel (n = 52)

Method No. positive No. equivocal Sensitivity (%)a 95% CI (%)a Sensitivity (%)b 95% CI (%)b
Enzygnost 49 2 94.2 83.1–98.5 98.1 88.4–99.9
Euroimmun 41 6 78.8 64.9–88.5 90.4 78.2–96.4
Euroimmun Nucleoprotein 39 6 75.0d 60.8–85.5 86.5 73.6–94.0
IBL 49 1 94.2 83.1–98.5 96.2 85.7–99.3
LIAISON XL 45 0 86.5 73.6–94.0 86.5 73.6–94.0
Microimmune 48 3 92.3 80.6–97.5 98.1 88.4–99.9
NovaLisa 49 0 94.2 83.1–98.5 94.2 83.1–98.5
Serion (activity calculator)c 51 0 98.1d 88.4–99.9 98.1 88.4–99.9
Serion (OD range)c 51 0 98.1d 88.4–99.9 98.1 88.4–99.9
Serion (special case formula)c 51 0 98.1d 88.4–99.9 98.1 88.4–99.9
a

Specimens with equivocal results counted as negative.

b

Specimens with equivocal results counted as positive.

c

Three methods of sample result determination, using the single set of optical density data from the test plates, were provided in the manufacturer’s IFU. All three methods were evaluated.

d

Significant difference (P < 0.05) between the most sensitive (Serion, all three result determination methods) and the least sensitive methods (Euroimmun NP) based on nonoverlapping 95% confidence intervals. This difference is only significant when equivocal results are counted as negative.